Press Releases

Woburn, MA – June 8, 2021 – Neurogastrx, Inc., a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced today that it has entered into an exclusive license agreement with Daewoong Pharmaceutical Co., Ltd., of Seoul, South Korea, for the development...

- JIM O'MARA NAMED CHIEF EXECUTIVE OFFICER - BOSTON, Jan. 4, 2018 /PRNewswire/ -- Neurogastrx, Inc., a private biopharmaceutical company focused on discovering and developing therapies for gastrointestinal disorders affecting the enteric nervous system, today announced a transformative $45M Series A financing co-led by 5AM Ventures, OrbiMed Advisors and venBio Partners. The funds will...